论文部分内容阅读
目的:探究溶血磷脂酸联合糖类抗原19-9检测对非小细胞肺癌的诊断价值。方法:本研究选择肺癌患者50例,同期良性肺疾病患者60例以及健康者50例,检测三组患者的CA19-9、LPA水平,以及比较联合检测方法和单独指标的灵敏度和特异度。结果:恶性组患者的血清中CA19-9、LPA水平远远高于良性组和对照组,结果差别显著,具有统计学意义(P<0.05);单独检测LAP、CA19-9的灵敏度、特异度分别为80%、57.27%,72%、59.10%;两种指标联合检测的灵敏度、特异度为96%、83.64%。结论:肺癌患者的血清中PLA、CA19-9水平显著高于良性肺部疾病患者以及健康者,同时对标志物的联合诊断较单独一种指标检测更加可靠,可以有效地提高灵敏度和特异度。
Objective: To investigate the diagnostic value of lysophosphatidic acid combined with carbohydrate antigen 19-9 in non-small cell lung cancer. Methods: In this study, we selected 50 patients with lung cancer, 60 patients with benign lung disease in the same period and 50 healthy people. The levels of CA19-9 and LPA were detected in three groups of patients, and the sensitivity and specificity of the combined detection methods and individual indexes were compared. Results: Serum levels of CA19-9 and LPA were significantly higher in malignant group than those in benign group and control group (P <0.05). Sensitivity and specificity of LAP and CA19-9 alone Respectively, 80%, 57.27%, 72%, 59.10%. The sensitivity and specificity of the combined detection of the two indexes were 96% and 83.64% respectively. Conclusion: The serum levels of PLA and CA19-9 in patients with lung cancer are significantly higher than those in patients with benign lung diseases and healthy people. Combined diagnosis of markers is more reliable than single index detection, which can effectively improve the sensitivity and specificity.